IOMED INTRODUCES NUMBY STUFF FOR PAINLESS NEEDLE INSERTION
Iomed traveled with the American Red Cross and demonstrated its technology in Washington, D.C. at the Red Cross National Headquarters; in Los Angeles at the California Science Center; in Atlanta, Ga., at the Turner Network Broadcast building; and in Detroit, at the Automotive Hall of Fame.
The Red Cross events featured technology demonstrations by Iomed and eight other companies whose various products are under consideration for use by the Red Cross. Numby Stuff eliminates the pain felt by most donors from insertion of the needle used to access the vein for blood donation.
"The invitation to exhibit at the American Red Cross' anniversary celebration presents us with a great opportunity," said Ned M. Weinshenker, Ph.D., president and chief executive officer of Iomed. "Local pain management was the objective behind the development of Numby Stuff and we hope that offering a pain-free needle insertion will encourage increased blood donations."
Developed by Iomed of Salt Lake City, Numby Stuff quickly and effectively delivers Iontocaine, Iomed's anesthetic medication, directly into the skin using a mild, low-level electrical current from a small, battery-powered dose controller. Within 10-15 minutes, the area becomes numb, making procedures such as the needle insertion for blood donations painless for the vast majority of patients.
Iomed's iontophoretic drug delivery systems have been used for many years by physical therapists and sports medicine specialists to treat a wide variety of local acute inflammatory conditions. Iomed adapted the technique for anesthesia after realizing its potential to significantly reduce or eliminate the pain of needle insertions and a variety of other local dermatological procedures.
The American Red Cross is the largest provider of blood, plasma and tissue in the United States. It provides nearly half of the nation's donations by working with more than 4.5 million donors and 3,000 hospitals annually through its network of 38 blood regions. In addition, the 18 Red Cross tissue centers nationwide provide one quarter of the tissue donations for transplantations in the United States.
Iomed, Inc., www.iomed.com is engaged in research, development, and manufacture of iontophoretic drug delivery systems to health care providers worldwide. Advanced research for local and systemic delivery of ionic pharmaceutical compounds to treat various medical conditions is conducted by its subsidiary, Dermion Inc. Iomed is based in Salt Lake City.
For more information, call 800/621-3347.
|Printer friendly Cite/link Email Feedback|
|Publication:||Biotech Equipment Update|
|Date:||Jul 1, 1998|
|Previous Article:||RISK IN TREND TO LINK REFRACTIVE LASERS TO CORNEAL TOPOGRAPHY|
|Next Article:||CARDIODYNAMICS GETS JAPANESE MINISTRY APPROVAL FOR BIOZ|
|ATME-I features nonwovens machinery.|
|IOMED INTRODUCES NEW DOSE CONTROLLER.|
|BUSINESS NOTES DIRECTORS GUILD OPPOSES WRITERS.|